AstraZeneca Says Trial Results For Breast Cancer Drug Were Highly Positive
By Christian Moess Laursen
AstraZeneca said trial results for its breast cancer drug Dato-DXd showed significant improvement for the primary end-point of so-called progression-free survival in patients.
The Anglo-Swedish pharma giant said Friday the drug--fully-named datopotamab deruxtecan--showed a statistical significant and clinically meaningful improvement compared with chemotherapy in patients with breast cancer.
The safety profile of the treatment was consistent with previous clinical trials in breast cancer with no new safety signals identified, it said.
Progression-free survival means the length of time during and after treatment of a disease, such as cancer, a patient lives with the disease without it getting worse.
Dato-DXd is being jointly-developed with Japan's Daiichi Sankyo.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
September 22, 2023 02:38 ET (06:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software